Clinical Significance of PD1 and PDL1 in Human Breast Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The programmed death 1 (PD1) and programmed death ligand 1 (PDL1) pathway can suppress antitumor immune responses.
• Emerging targeted therapies focus on PDL1, necessitating a clearer understanding of its role in breast cancer.

Purpose of the Study:

• To investigate the clinical significance of PD1 and PDL1 mRNA expression in breast cancer.
• To explore the association of PD1 and PDL1 expression with disease progression and patient prognosis.

Main Methods:

• Quantitative polymerase chain reaction (qPCR) was used to measure PD1 and PDL1 transcript levels.
• Analysis included 127 primary breast cancer tissues and 33 matching non-neoplastic tissues.
• Statistical methods included t-tests, Kaplan-Meier survival analysis, and Wilcoxon tests.

Main Results:

• PDL1 transcript levels were significantly reduced in patients who developed metastases or local recurrence.
• Higher PDL1 transcript levels correlated with improved overall and disease-free survival.
• PD1 transcript levels were significantly higher in tumor tissues; PDL1 showed a non-significant increase in tumors.

Conclusions:

• Elevated PDL1 expression is associated with a favorable clinical outcome in breast cancer patients.
• PDL1 transcript levels may serve as a prognostic biomarker for breast cancer progression.